The DIAN-TU trial, sponsored by Washington University School of Medicine, is a pivotal study investigating the efficacy of E2814, an anti-tau therapy, in combination with lecanemab, an investigational amyloid removal drug, for individuals with dominantly inherited Alzheimer's disease (DIAD). The trial targets a niche but critical segment of the Alzheimer's market, focusing on genetically predisposed patients. Given the increasing prevalence of Alzheimer's disease and the urgent need for effective disease-modifying therapies, successful outcomes could position the involved entities favorably in a competitive landscape characterized by high unmet medical need. The collaboration with Eisai Inc. and support from various NIH grants further enhances the credibility and potential market access of the investigational therapies. However, the trial's complexity and the stringent eligibility criteria may limit patient recruitment and generalizability of results.